Revision of Micafungin from Mar 14, 2022

Dosing: Adult Antimicrobial Dosing, Non-dialysis

Indication Dose Notes
Esophageal candidiasis 150 mg IV daily

 

 

Dosage adjustment not required in renal or hepatic dysfunction

Prophylaxis against Candida in patients with HSCT, neutropenia, hematologic malignancy, or solid organ transplant 50-100 mg IV daily

Candidemia

Invasive candidiasis

Empiric treatment, febrile neutropenia

Empiric treatment, non-neutropenic ICU patients

100 mg IV daily

Dosing: Antimicrobial Dosing in Intermittent & Continuous Hemodialysis

Indication Dose Notes
Esophageal candidiasis 150 mg IV daily

 

 

Dosage adjustment not required in hemodialysis

Prophylaxis against Candida in patients with HSCT, neutropenia, hematologic malignancy, or solid organ transplant 50-100 mg IV daily

Candidemia

Invasive candidiasis

Empiric treatment, febrile neutropenia

Empiric treatment, non-neutropenic ICU patients

100 mg IV daily

Dialysis Notes

Intermittent HD assumes high-flux hemodialysis. CRRT assumes CVVHD with ultrafiltration rate 2L/h and residual native GFR < 10 mL/min.  For detailed view of dialysis dosing and evidence, see Dosing in Hemodialysis document.

Restricted to ID or Antimicrobial Stewardship except:

1) Documented sterile site (not urine or respiratory) infection  with microbiologically confirmed Candida glabrata or Candida kruseii

2) Documented sterile site infection (not urine or respiratory) infection with yeast, pending species identification

3) Prophylaxis against fungal infections in patients on the hematology/oncology/BMT service with intolerance of or contraindications to azoles

4) Empiric therapy for prolonged febrile neutropenia in hematology/oncology/BMT patient

References: